Edition:
United Kingdom

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

11.34USD
8:03pm BST
Change (% chg)

$-0.36 (-3.08%)
Prev Close
$11.70
Open
$11.76
Day's High
$11.93
Day's Low
$11.25
Volume
83,292
Avg. Vol
138,666
52-wk High
$12.10
52-wk Low
$2.62

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD
Thursday, 16 May 2019 

May 16 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES UPDATE ON OPTIC PHASE 1 TRIAL FOR ADVM-022 IN WET AMD.ADVERUM BIOTECHNOLOGIES INC - U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED CLINICAL HOLD ON ADVM-022.ADVERUM BIOTECHNOLOGIES - FDA LIFTED CLINICAL HOLD ON SECOND COHORT, ADVM-022 REMAINS ON PARTIAL CLINICAL HOLD FOR DOSING PATIENTS IN THIRD COHORT.ADVERUM BIOTECHNOLOGIES INC - ADVERUM WILL CONTINUE TO WORK CLOSELY WITH FDA TO RESOLVE REMAINING CMC COMMENTS..  Full Article

Adverum Biotechnologies Announces Board Changes
Thursday, 2 May 2019 

May 2 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES BOARD CHANGES.ADVERUM BIOTECHNOLOGIES INC - PATRICK MACHADO APPOINTED AS BOARD CHAIR; PAUL CLEVELAND RETIRES FROM BOARD.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DIRECTORS REKHA HEMRAJANI, JAMES SCOPA AND MARK LUPHER ADDED TO BOARD.ADVERUM BIOTECHNOLOGIES INC - BOARD CONSISTS OF NINE DIRECTORS, EIGHT OF WHOM ARE INDEPENDENT.  Full Article

Adverum Biotechnologies Q3 Loss Per Share $0.34
Thursday, 8 Nov 2018 

Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.34.Q3 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.QTRLY COLLABORATION AND LICENSE REVENUE $833,000 VERSUS $463,000.Q3 REVENUE VIEW $380000.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Adverum Biotechnologies Receives Fast Track Designation For ADVM-022 Gene Therapy For The Treatment Of wAMD
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES RECEIVES FAST TRACK DESIGNATION FOR ADVM-022 GENE THERAPY FOR THE TREATMENT OF wAMD.ADVERUM BIOTECHNOLOGIES INC SAYS OPTIC PHASE 1 CLINICAL TRIAL INITIATION EXPECTED IN 4Q18.ADVERUM BIOTECHNOLOGIES - FAST TRACK DESIGNATION INTENDED TO FACILITATE DEVELOPMENT, EXPEDITE REVIEW OF DRUGS AND BIOLOGICS.  Full Article

Adverum Biotechnologies Q4 Loss Per Share $0.32
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.32.  Full Article

Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.89 MILLION COMMON SHARES PRICED AT $6.75PER SHARE.PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 8.8 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $6.75 PER SHARE.  Full Article

Adverum Biotechnologies Announces Proposed Public Offering
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADVERUM BIOTECHNOLOGIES - INTENDS TO GRANT UNDERWRITERS 30-DAY OPTION TO BUY UP TO ADDITIONAL 15% OF SHARES OF COMMON STOCK OFFERED IN PUBLIC OFFERING.  Full Article

Adverum Biotechnologies Provides 2018 Outlook
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017..ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019.ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA.  Full Article

Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Adverum Biotechnologies Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING.  Full Article

Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY.ADVERUM BIOTECHNOLOGIES INC - ‍COMPANY EXPECTS TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018​.  Full Article